Nature Communications (Feb 2017)
Covalent assembly of nanoparticles as a peptidase-degradable platform for molecular MRI
- Francisco Perez-Balderas,
- Sander I. van Kasteren,
- Alaa A. A. Aljabali,
- Kim Wals,
- Sébastien Serres,
- Andrew Jefferson,
- Manuel Sarmiento Soto,
- Alexandre A. Khrapitchev,
- James R Larkin,
- Claire Bristow,
- Seung Seo Lee,
- Guillaume Bort,
- Filippo De Simone,
- Sandra J. Campbell,
- Robin P. Choudhury,
- Daniel C. Anthony,
- Nicola R. Sibson,
- Benjamin G. Davis
Affiliations
- Francisco Perez-Balderas
- Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford
- Sander I. van Kasteren
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford
- Alaa A. A. Aljabali
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford
- Kim Wals
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford
- Sébastien Serres
- Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford
- Andrew Jefferson
- Department of Cardiovascular Medicine and Oxford Acute Vascular Imaging Centre, University of Oxford, John Radcliffe Hospital
- Manuel Sarmiento Soto
- Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford
- Alexandre A. Khrapitchev
- Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford
- James R Larkin
- Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford
- Claire Bristow
- Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford
- Seung Seo Lee
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford
- Guillaume Bort
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford
- Filippo De Simone
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford
- Sandra J. Campbell
- Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford
- Robin P. Choudhury
- Department of Cardiovascular Medicine and Oxford Acute Vascular Imaging Centre, University of Oxford, John Radcliffe Hospital
- Daniel C. Anthony
- Department of Pharmacology, University of Oxford
- Nicola R. Sibson
- Department of Oncology, Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford
- Benjamin G. Davis
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford
- DOI
- https://doi.org/10.1038/ncomms14254
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 10
Abstract
Iron oxide microparticles (MPIO) are better MRI contrast agents than nanoparticles, but are of limited clinical use as they are not degradable and so risk toxicity. Here the authors present an iron oxide microparticle MRI contrast agent with peptide linkers that enable degradation into non-toxic nanoparticlesin vivo.
